Company news

Heilongjiang Zbd Pharmaceutical Co., Ltd. Class A (SSE:603567) news

Heilongjiang Zbd Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 4, 2026: "Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement…

Heilongjiang Zbd Pharmaceutical Co., Ltd. Class A (SSE:603567) news

Press releases & updates

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Pledge of Certain Shares Held by the Controlling Shareholder

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Semi-annual Report for 2026

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Change of Sponsor Representative for Continuous Supervision

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Progress of Provision of Guarantee for an Investee Company

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Provision of Guarantee Limit for Wholly-owned Subsidiary

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Abnormal Fluctuations in Stock Trading

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Notice on Convening the 3rd Extraordinary General Meeting in 2026

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Partial Restricted Stocks under 2023 Restricted Stock Incentive Plan

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Partial Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report

"Heilongjiang ZBD Pharmaceutical Co., Ltd."Indicative Announcement on the Proposed Extension of the Pledge of Certain Shares Held by the Controlling Shareholder

Indicative Announcement on Proposed Extension of Pledge of Partial Shares by the Controlling Shareholder

Announcement on Extension of Pledge of Partial Shares by the Controlling Shareholder

Announcement on Providing Guarantee for Wholly-owned Subsidiary

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Notice on Convening the 2nd Extraordinary General Meeting in 2026

Announcement on Inability to Timely Repay the Raised Funds Temporarily Used to Supplement Working Capital

Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiaries

Announcement on Proposed Inclusion of Some Drugs in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance

Announcement on Completion of the Pledge Release on the Remaining Pledged Shares of the Non-publicly Issued Exchangeable Corporate Bonds by the Controlling Shareholder

Special Report on Deposit, Management and Actual Use of Raised Funds in 2025

Announcement on Postponement of Disclosure of 2025 Annual Report

Announcement on Implementing Cancellation of Repurchased Shares and Share Changes

Indicative Announcement on Premature Delisting of the Non-public Offering of Exchangeable Corporate Bonds by the Controlling Shareholder (Phase II) and the Proposed Release of the Remaining Pledged Shares

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Indicative Announcement on Change in Equity of Controlling Shareholder

Indicative Announcement on Completion of the Delisting of the Non-public Offering of Exchangeable Corporate Bonds by the Controlling Shareholder (Phase I) and the Proposed Release of the Remaining Pledged Shares

Indicative Announcement on Change in Equity of Controlling Shareholder Reaching 1% Scale

Announcement on Completion of Supplemental Share Pledge Procedures for the Non-publicly Issued Exchangeable Corporate Bonds by the Controlling Shareholder

Indicative Announcement on Adjusting Conversion Price of Non-publicly Issued Exchangeable Corporate Bonds Held by Controlling Shareholders

Notice on Convening the 1st Extraordinary General Meeting in 2026

Indicative Announcement on Controlling Shareholder’s Proposed Supplementary Pledge of Shares for the Non-public Issuance of Exchangeable Corporate Bonds

Announcement on Resignation of Chairman of the Board of Directors, Election of a New Chairman and Adjustment of Members of Special Committees of Board of Directors

Announcement on Obtaining Notice of Approval for Marketing Application of Chemical APIs of Branch

Announcement on Earnings Preannouncement for 2025

Announcement on Pledge and Release of Pledge of Partial Shares of Controlling Shareholders

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares

Announcement on Providing Additional Guarantee Amount for Wholly-owned Subsidiary

Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary

Announcement on Renewing Engagement of Accounting Firm

Report for Q3 2025

Indicative Announcement on Change in Equity of Shareholder with Over 5% Shares to Less than 5%

Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 5%

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Shareholding Reduction Plan for Shareholders Holding More than 5% of Shares